Amcasertib/Napabucasin

N/A

Report date: 2022/03/17 14:56:08

Base Information

Drug NameAmcasertib/Napabucasin
Drug Alias NameBBI-608 + BBI-503Amcasertib+NapabucasinNapabucasin+AmcasertibNapabucasin/Amcasertibnapabucasin + amcasertib +[7] 
ClassificationSmall molecules
Mechanisms of ActionSignal transducer and activator of transcription 3 inhibitorsSerine/threonine-protein phosphatase inhibitors
TargetsSerine/threonine-protein phosphataseSignal transducer and activator of transcription 3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes AmcasertibNapabucasin
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoston Biomedical Inc
China Registration ClassN/A

Develop Information

Active CompaniesBoston Biomedical Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A